UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy
UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy
瑞銀將信和生物製藥的目標股價從8港元調整至7.5港元，維持買入
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間